What type of study is this?

September 5, 2025Frontiers in OncologyOpen Access

Effectiveness and safety profile of chidamide as maintenance therapy for peripheral T-cell lymphoma: a multicenter real-world study

View Full Paper

Ask AI

Bookmark

Authors

WJWenjing JiangGuangdong Academy of Medical Sciences XZXiyuan ZhangQingdao University WSWei SongQingdao University

Discussion

Member takes

Implication

Real-world analysis demonstrates improved outcomes for patients with peripheral T-cell lymphoma, indicating the effectiveness of chidamide in maintenance therapy.

Key Points

Chidamide as maintenance therapy improved prognosis in patients with peripheral T-cell lymphoma.
Overall survival rate was not achieved, while the median progression-free survival was 54.8 months.
Patients attaining complete response showed significantly better outcomes in progression-free survival.
The safety profile included a 20.3% rate of severe adverse events, notably neutropenia.

Cite This Study

Jiang et al. (2025) studied this question.

synapsesocial.com/papers/68bb4df56d6d5674bcd02120 https://doi.org/10.3389/fonc.2025.1596270

View Full Paper

Ask AI

Bookmark

Implication

Real-world analysis demonstrates improved outcomes for patients with peripheral T-cell lymphoma, indicating the effectiveness of chidamide in maintenance therapy.

Effectiveness and safety profile of chidamide as maintenance therapy for peripheral T-cell lymphoma: a multicenter real-world study

Discussion

Member takes

Implication

Key Points

Cite This Study

Effectiveness and safety profile of chidamide as maintenance therapy for peripheral T-cell lymphoma: a multicenter real-world study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider